The renal transcriptome of db/db mice identifies putative urinary biomarker proteins in patients with type 2 diabetes: A pilot study

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 7, 2012, Pages

  Simonson, Michael S ^a   Tiktin, Margaret ^a   Debanne, Sara M ^a   Rahman, Mahboob ^a,b   Berger, Bruce ^a   Hricik, Donald ^a   Ismail Beigi, Faramarz ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Diabetic kidney disease; Gene expression profiling

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; ENDOTHELIN 1; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; URINE LEVEL;

EID: 84859471247     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00424.2011     Document Type: Article

References (57)

1. Afkarian M, Bhasin M, Dillon ST, Guerrero MC, Nelson RG, Knowler WC, Thadhani R, Libermann TA. Optimizing a proteomics platform for urine biomarker discovery. Mol Cell Proteomics 9: 2195-2204, 2010.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 31, Suppl 1: S55-S60, 2008.
3. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis SE, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene Ontology: tool for the unification of biology. Nat Genet 25: 25-29, 2000.
4. Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 168: 2440-2447, 2008.
5. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 57: 289-300, 1995.
6. Bennett CN, Green JE. Unlocking the power of cross-species genomic analysis: identification of evolutionarilly conserved breast cancer networks and validation of preclinical models. Breast Cancer Res 10: 213, 2008.
7. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, Buemi M. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 32: 91-98, 2009.
8. Brosius FC III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T, and for the Animal Models of Diabetic Complications Consortium. Mouse models of diabetic nephropathy. J Am Soc Nephrol 20: 2503-2512, 2009.
9. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wit-twer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622, 2009.
10. Candiano G, Santucci L, Petretto A, Bruschi M, Dimuccio V, Urbani A, Bagnasco S, Ghiggeri GM. 2D-electrophoresis and the urine proteome map: where do we stand? J Proteomics 73: 829-844, 2010.
11. Caramori ML, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol 17: 339-352, 2006.
12. Carstensen M, Herder C, Brunner EJ, Strassburger K, Tabak AG, Roden M, Witte DR. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol 162: 913-917, 2010.
13. D'Amico G, Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens 12: 639-643, 2003.
14. Decleves AE, Sharma K. New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 6: 371-380, 2010.
15. Decramer S, de Peredo AG, Breuil B, Mischak H, Monsarrat B, Bascands JL, Schanstra JP. Urine in clinical proteomics. Mol Cell Proteomics 7: 1850-1862, 2008.
16. Dennis G, Sherman B, Hosack D, Yang J, Gao W, Lane HC, Lempicki R. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3, 2003.
17. Dhaun N, Lilitkarntakul P, Macintyre IM, Muilwijk E, Johnston NR, Kluth DC, Webb DJ, Goddard J. Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 296: F1477-F1483, 2009.
18. Dostalova I, Roubicek T, Bartlova M, Mraz M, Lacinova Z, Haluz-ikova D, Kavalkova P, Matoulek M, Kasalicky M, Haluzik M. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol 161: 397-404, 2009.
19. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998.
20. Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA Jankowski J, Mischak H. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 18: 1057-1071, 2007.
21. Foley RN, Collins AJ. The growing economic burden of diabetic kidney disease. Curr Diab Rep 9: 940-465, 2009.
22. Glassock RJ. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 31: 462-465, 2010.
23. Goddard J, Johnston NR, Cumming AD, Webb DJ. Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. Am J Physiol Renal Physiol 293: F1433-F1438, 2007.
24. HKUPP. Human Kidney and Urine Proteome Project: A tentative standard protocol for urine collection and storage (Online). Niigata, Japan: HKUPP. http://www.hkupp.org [2010].
25. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Urinary transforming growth factor- fj excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 25: 1072-1077, 2002.
26. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2008.
27. Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13, 2009.
28. Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ. New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 82, Suppl 1: S30-S37, 2008.
29. Kern EFO, Erhard P, Sun W, Genuth S, Weiss MF. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis 55: 824-834, 2010.
30. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289: 3273-3277, 2003.
31. Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 33: 1567-1572, 2010.
32. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 54: 205-226, 2009.
33. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254, 2006.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-AACT method. Methods 25: 402-408, 2001.
35. Lu Y, Huggins P, Bar-Joseph Z. Cross species analysis of microarray expression data. Bioinformatics 25: 1476-1483, 2009.
36. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in Type 2 diabetes. Diabetes Care 27: 195-200, 2004.
37. Matheson A, Wilcox MDP, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 26: 150-171, 2010.
38. Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, Danne T, Haller H, Fliser D, Mischak H. Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephrop-athy by a novel combined proteome analysis. J Diabetes Complications 19: 223-232, 2005.
39. Merchant ML, Klein JB. Proteomics and diabetic nephropathty. Semin Nephrol 27: 627-636, 2007.
40. Merchant ML, Perkins BA, Boratyn GM, Ficociello LH, Wilkey DW, Barati MT, Bertram CC, Page GP, Rovin BH, Warram JH, Krolewski AS, Klein JB. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 20: 2065-2074, 2009.
41. Mishra R, Emancipator SN, Miller C, Kern T, Simonson MS. Adipose differentiation related protein and regulators of lipid homeostasis identified by gene expression profiling in murine db/db diabetic kidney. Am J Physiol Renal Physiol 286: F913-F921, 2004.
42. Mishra R, Simonson MS. Oleate induces a myofibroblast-like phenotype in mesangial cells. Arterioscler Thromb Vasc Biol 28: 541-547, 2008.
43. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 89-93, 1984.
44. Nauta FL, Boertien WE, Bakker SJ, van Goor H, van Oeveren W, de Jong PE, Bilo H, Gansevoort RT. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34: 975-981, 2011.
45. Parving HH, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol 100: 550-555, 1982.
46. Retnakaran R, Cull CA, Thorme KI, Adler AI, Holman RR, Group US. Risk factors for renal dysfunction in type 2 diabetes. UK Prospective Diabetes Study 74. Diabetes 55: 1832-1839, 2006.
47. Rossing K, Mischak H, Dakna M, Zurbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 19: 1283-1290, 2008.
48. Saha SA, Tuttle KR. Influence of glycemic control on the development of diabetic cardiovascular and kidney disease. Cardiol Clin 28: 497-516, 2010.
49. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284: F1138-F1144, 2003.
50. Tesch GH, Lim AKH. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol 300: F301-F310, 2011.
51. Thomas CE, Sexton W, Benson K, Sutphen R, Koomen J. Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol Biomarkers Prev 19: 953-959, 2010.
52. Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment co-existing with NIDDM [NEFRON] 11). Diabetes Care 32: 1497-1502, 2009.
53. Thongboonkerd V. Searching for novel biomarkers and new therapeutic targets of diabetic nephropathy using proteomic approaches. Contrib Nephrol 160: 37-52, 2008.
54. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300: R1009-R1022, 2011.
55. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1: 1430-1432, 1982.
56. Vupputuri S, Nichols GA, Lau H, Joski P, Thorp ML. Risk of progression of nephropathy in a population-based sample with type 2 diabetes. Diabetes Res Clin Pract 91: 246-252, 2011.
57. Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 24: 1212-1219, 2009.